Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Terns Pharmaceuticals, Inc. - Common Stock
(NQ:
TERN
)
8.260
+0.100 (+1.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Terns Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why Is Terns Pharmaceuticals Stock Trading Lower After Obesity Trial Data?
October 22, 2025
Terns Pharmaceuticals announces 12-week Phase 2 results for oral obesity drug TERN-601, showing up to 4.6% weight loss but reporting cases of drug-induced liver injury.
Via
Benzinga
Netflix Posts Downbeat Earnings, Joins Aveanna Healthcare, Texas Instruments And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
October 22, 2025
Via
Benzinga
Why Intuitive Surgical Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
October 22, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 21, 2025
Via
Benzinga
Which stocks are moving after the closing bell on Tuesday?
October 21, 2025
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.
Via
Chartmill
Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity
October 21, 2025
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
October 02, 2025
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
2 Under-the-Radar Stocks That Could Soar
September 21, 2025
They could ride the wave of the hottest therapeutic area in the industry.
Via
The Motley Fool
Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025
August 21, 2025
Webinar to be held on Wednesday, September 3, 2025 at 4:30 p.m. ET
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations
August 07, 2025
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the...
Via
MarketMinute
Topics
Economy
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
August 07, 2025
Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates.
Via
Benzinga
Terns (TERN) Q2 Net Loss Narrows 16%
August 06, 2025
Via
The Motley Fool
Topics
Intellectual Property
Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
August 05, 2025
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
August 04, 2025
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
June 23, 2025
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
June 20, 2025
Via
Benzinga
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday
June 10, 2025
Via
Benzinga
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
May 29, 2025
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
May 14, 2025
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
May 08, 2025
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
May 02, 2025
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference
April 30, 2025
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
April 02, 2025
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
March 20, 2025
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street
March 09, 2025
Via
The Motley Fool
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)
February 26, 2025
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference
February 25, 2025
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer
February 24, 2025
Seasoned public company CFO with 25 years of leadership experience in biotech
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors
February 20, 2025
Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertise
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 05, 2025
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.